外体微RNA-22通过调节骨髓瘤中Twist1/CADM1轴来抑制扩散,迁移和入侵
Qing Ruan1, Cuijie Wang2, Yuntao Wu1
1Department of Orthopedics of the China-Japan Union Hospital of Jilin University, Sendai Street 126, Changchun, 130033, Jilin, China.
Scientific reports
|January 9, 2024
概括
介质干细胞 (MSC) 外体所传递的微RNA-22 (miR-22) 通过准Twist1.1,抑制骨髓瘤 (OS) 的生长和传播. 这种基于外体的疗法为OS治疗提供了一个有前途的策略.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 生物技术是生物技术.
背景情况:
- 骨髓瘤 (OS) 是一种具有高转移潜力的原发性骨恶性瘤.
- 微RNAs (miRNAs) 在癌症的发展和进展中起着至关重要的作用.
- 介质干细胞 (MSC) 和它们的外体正在成为潜在的治疗输送载体.
研究的目的:
- 研究MSCs中的miR-22在调节骨髓瘤 (OS) 细胞增殖,迁移和入侵中的功能.
- 在OS治疗中探索外体递送miR-22的治疗潜力.
- 阐明OS中涉及miR-22,Twist1和CADM1的分子机制.
主要方法:
- 生物信息分析 (GEO2R,基因本体学) 用于识别目标基因.
- 通过RT-qPCR和西部斑点测试来评估基因和蛋白质的表达.
- 细胞增殖试验 (MTS,CCK8,殖民地形成,EDU).
- 细胞迁移和入侵试验 (Transwell,伤口愈合).
- 路西法酶记者测定以确认miRNA-目标相互作用.
- 外体隔离,标记 (PKH-26) 和细胞吸收研究.
主要成果:
- 在OS组织和细胞系中,miR-22和CADM1的调节下降,而Twist1的调节上升.
- 在OS细胞中miR-22的过度表达显著抑制了增殖,迁移和入侵.
- 证实Twist1是miR-22.2的直接目标.
- 与未经修改的exo-MSC相比,装载着miR-22模仿的MSC (exo-MSC) 衍生出的外体显示出OS细胞行为的增强抑制.
- 通过外MSC通过OS细胞吸收miR-22,通过准Twist1.1,有效地抑制了瘤进展.
结论:
- 在骨髓瘤中,miR-22通过抑制增殖,迁移和入侵,起到瘤抑制作用.
- 通过外体介导的miR-22的输送代表了骨髓瘤的强有力的治疗策略.
- 针对miR-22/Twist1轴为骨髓瘤治疗提供了一种新的方法.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Destabilization of Microtubules
2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


